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ABSTRACT
The dynamics of biological processes depend on
the structure and flexibility of the interacting mole-
cules. In particular, the conformational diversity of
DNA allows for large deformations upon binding.
Drug–DNA interactions are of high pharmaceutical
interest since the mode of action of anticancer,
antiviral, antibacterial and other drugs is directly
associated with their binding to DNA. A reliable pre-
diction of drug–DNA binding at the atomic level
by molecular docking methods provides the basis
for the design of new drug compounds. Here, we
propose a novel Monte Carlo (MC) algorithm for
drug–DNA docking that accounts for the molecular
flexibility of both constituents and samples the
docking geometry without any prior binding-site
selection. The binding of the antimalarial drug methy-
lene blue at the DNA minor groove with a preference
of binding to AT-rich over GC-rich base sequences
is obtained in MC simulations in accordance with
experimental data. In addition, the transition between
two drug–DNA-binding modes, intercalation and
minor-groove binding, has been achieved in depen-
dence on the DNA base sequence. The reliable ab
initio prediction of drug–DNA binding achieved by
our new MC docking algorithm is an important step
towards a realistic description of the structure and
dynamics of molecular recognition in biological
systems.
INTRODUCTION
Ligand binding to macromolecules plays a key role in biology
and medicine as steering mechanism in biological processes.
More specifically, the binding of drugs to proteins and DNA
has been of great interest in recent years leading to a large
body of structural studies using both experimental and
theoretical methods. Owing to the central role of DNA in
replication and transcription, DNA has been a major target
for antibiotic, anticancer and antiviral drugs (1). The effects
of nucleic acid binding drugs are known for various diseases
such as cancer, malaria, AIDS and other viral, bacterial and
fungal infections (2). The majority of DNA drugs are aromatic
compounds of low molecular weight often carrying positive
charges (3). The different modes of drug binding to DNA
include intercalation between adjacent base pairs, intrusion
into the minor groove and into the major groove. Intercalation
and minor-groove binding are the predominant DNA-binding
modes of small ligands (2–4). Sequence specificity of drug–
DNA binding is limited owing to the restricted size of drugs
but is generally higher for minor-groove binders than for
intercalators (2,3).
Atomic-resolution structures of drug–DNA complexes
have been reported by X-ray crystallography and NMR spec-
troscopy (4–8). Most of the DNA intercalating drugs show
preferences to bind sequences of alternating purine and
pyrimidine bases and GC-rich sequences (2,6). Intercalation
requires a major deformation owing to the formation of a
binding cavity (3,4), in contrast to minor-groove binding
that does not require major conformational changes of the
DNA (3). The majority of DNA-binding drugs binds at the
minor groove of B-DNA and show a higher affinity for
AT-rich sequences (4,7,9). The minor groove of sequences
with alternating A and T bases is generally narrow allowing
favorable van der Waals contacts between the drug and the
DNA (4,8) in contrast to GC-rich sequences where bulky
amino groups of guanine bases at the minor groove affect
the groove geometry (2,7). The advancement in understanding
sequence-specific drug–DNA recognition allows for designing
improved new drugs (8). The DNA major groove offers
more specific contacts for establishing hydrogen bonds with
the drug but van der Waals contacts are less favorable owing
to groove dimensions (2). Also, the major groove is often
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occupied by proteins whose biological activity can be affected
by minor-groove binding drugs (2). Drug–DNA binding is in
most cases non-covalent although covalent bonds may be
formed with reactive ligands (3,4).
Studies on the prediction of interaction modes between
biological molecules have been always a major driving
force in the development of molecular modeling algorithms.
Studies on drug–DNA binding were performed in order to
elucidate the energetic origins of the binding in terms of inter-
molecular forces and induced conformational changes and
to develop new drug design strategies (10–13). Thermo-
dynamic studies have analyzed drug binding to DNA in
terms of free energy as the interplay between unfavorable
deformations and entropy losses on one hand and favorable
hydrophobic, electrostatic and van der Waals contributions
on the other (11–14). Molecular modeling studies of drug–
DNA interactions have been limited owing to the complexity
of such systems. Therefore, binding-site predictions are often
biased by a prior ligand positioning relative to the target
molecule (15). Molecular dynamics (MD) simulations of
drug–DNA complexes were reported for timescales <10 ns
providing information on the flexibility of the structure of the
complex within a single energy minimum (14,16). A sufficient
sampling of the conformational space including transitions
between different energy minima requires longer time scales
that are not reachable in state-of-the-art MD simulations (15).
In contrast to contemporary methods, a novel Monte Carlo
(MC) approach for nucleic acids has been successful in
sampling the structure and flexibility of papillomavirus
E2-DNA-binding sites providing new insights into the origins
of intrinsic DNA bending (17,18).
Molecular docking is a computational method for pre-
dicting ligand–receptor binding when both the binding site
and binding mode are unknown (19). Docking studies were
focused mainly on protein-related systems and have been
restricted until recently to rigid molecules of either one or
both constituents of the complex (19–22). Recent develop-
ments include partial flexibility in the docking process (23),
either directly by applying certain degrees of freedom such
as side chain rotations (24–27) or by docking an ensemble of
conformations of the target molecules (28–32). In addition,
previous docking approaches for small ligands were biased
by prior binding-site definitions (20,22,27,28). The number
of docking studies that involve DNA is very small and in
these studies DNA was treated as a rigid molecule although
nucleic acids are in general much more flexible than proteins
(33–36). Limited conformational flexibility of DNA was
included by modifying specific structural parameters such
as overall winding and bending (37). Several studies applied
MC methods for either rigid body moves of the DNA and
protein components in the docking process (33,34,37) or
post-docking energy minimizations (38). Docking algorithms
are based on reduced atom representations (30,33), all-atom
force fields (34,37) or knowledge-based potentials for specific
ligand–DNA interactions (39).
This study presents a new docking algorithm that combines
full flexibility of both the DNA and the ligand with an all-atom
force field. The proposed algorithm is an ab initio docking
method without any bias in the binding-site sampling. Both the
moves of the drug and the DNA target relative to each other
and the internal flexibility of the two molecules are defined
by MC variables. The docking method is based on the
assumption of fixed bond lengths (17). We have chosen to
demonstrate the method of flexible MC docking to methylene
blue (MB)–DNA binding because the binding mode in this
system depends on the DNA base sequence and not on the
propensity of the drug to act as a minor-groove binder or an
intercalator. The structural information on MB binding to
DNA is based on spectroscopic data suggesting that MB
binds preferentially at the minor groove of DNA with alter-
nating AT bases and intercalates into DNA of the analogous
alternating GC sequence (40) in accordance with energy
minimization studies (41–43). Owing to the sequence depen-
dence of MB–DNA binding, this system is appropriate for
the assessment of a novel ab initio docking method because
the choice of the drug doesn’t imply any prior binding-
geometry definition. MB has drug-like structural properties
including cationic charge and an extended aromatic system.
Also, MB has only four rotatable methyl groups as internal
degrees of freedom. MB is a phenothiazinium dye whose
photosensitizing and antimalarial activity accounts for its
pharmacological importance (44,45). Our flexible ab initio
docking of MB to DNA and the MC sampling of MB–
DNA-binding sites and binding modes provide new insights
into the sequence dependence of drug–DNA binding.
MATERIALS AND METHODS
The flexible drug–DNA docking and conformational sampl-
ing of drug–DNA binding are based on a new MC approach
developed for DNA (46,47). Based on the constant bond
length approximation, the MC algorithm combines collective
with internal variable moves. Each nucleotide is described by
rigid-body translations and rotations (six collective variables)
complemented by variations of the sugar phase and amplitude,
the glycosidic angle, two endocyclic torsion and one endocyc-
lic bond angle of the DNA backbone (six internal variables).
This set of 12 variables per nucleotide, complemented by
rotations of the thymine methyl groups, ensures local MC
moves but results in DNA strand breaks. The DNA backbone
is closed after each chain breakage by an analytical method
defined in the torsion and bond angle space (47). Thus, all
endocyclic torsion and bond angles are varied either as inde-
pendent MC or dependent closure variables. Explicit sodium
ions electro-neutralize the polyanionic system and their Car-
tesian coordinates are used to define MC moves of the counter
ions. Energy calculations are based on the Cornell et al. (48)
AMBER force field. In addition, an implicit solvent des-
cription (49,50) is used and a force field artifact in favor of
non-canonical backbone conformation has been corrected
(46). The MC algorithm for nucleic acids has been shown
to result in fast equilibration and efficient conformational
sampling (17).
Herein, we propose a new MC algorithm for ab initio drug
docking to DNA. The entirety of MC variables for nucleic
acids and counter ions, whose modifications comprise one MC
cycle, includes rigid-body translations and rotations of the
ligand relative to the DNA and additional internal variables
describing the internal flexibility of the specific drug. A
ligand-based reference axes system has been defined (41),
and the MB molecule is translated and rotated relative to
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the DNA global helix axis and a central reference nucleotide
(six collective variables). As shown in Figure 1, MB is a planar
heterocyclic molecule that contains four rotatable methyl
groups representing its flexibility within the approximation
of fixed bond lengths and a rigid aromatic system (four internal
variables). Thus, 10 MC variables have been added for the
entirely flexible treatment of MB–DNA complexes in MC
simulations. In view of the cationic charge of MB, the number
of counter ions was adjusted to ensure electro-neutrality. The
drug and the counter ions move freely within a cylinder around
the DNA helix of a radius of 100 s from the global helix axis
and a height of twice the DNA length. Both drug and ions are
reflected from the cylinder’s inner surface if they cross the
cylinder borders.
The MC docking simulations were performed with MB
initially placed at the periphery of the DNA surrounding
cylinder. For statistical reasons, MC simulations were started
from 20 different initial configurations with MB at distances
of 30–100 s from the central DNA base pairs. The docking
target used is a DNA dodecamer of the sequence 50-
GCGCGCATATAT-30. The combination of two hexamers
of different sequences of alternating bases, referred to as
GC-tract and AT-tract, enables docking simulations that
search for base sequence preferences in addition to estab-
lishing the binding mode. The purine–pyrimidine alternat-
ing sequences have been chosen because the available
spectroscopic data were reported for such DNA targets
(40). The MC docking simulations comprise 500 MC kcycles
each providing only a rough sampling of binding sites rather
than full equilibration.
In order to obtain a comprehensive sampling of binding sites
and binding modes, MC simulations were started from pre-
viously reported conformations of MB bound to DNA (41,43).
To explore base sequence effects on drug–DNA binding,
MC simulations were performed on MB binding to DNA
dodecamers with alternating AT or alternating GC base
sequences. These MC simulations of MB–DNA complexes
were performed with 2000 MC kcycles in order to achieve
full equilibration. Thus, two aspects of drug–DNA recognition
namely docking and binding-mode sampling are combined in
this study.
RESULTS AND DISCUSSION
Flexible ab initio MB–DNA docking
Docking simulations were started from 20 different configura-
tions with MB off the center of the DNA target by either a
radial distance of 90 s on average (85% of the trials) or an
axial distance of 34 s on average (15%). The docking of
MB to DNA was achieved in all docking trials with a stable
MB–DNA binding established within the initial 3–26 MC
kcycles, as stated in Table 1. The docking process is illustrated
for the energetically best-rated prediction by the following:
(i) in terms of X-displacement and Y-displacement of MB
(Figure 1), (ii) by MC snapshots throughout the docking
process and initial binding-site sampling (Figure 2) and (iii)
in terms of Rise of MB and total energy of the MB–DNA
complex including sodium counter ions (Figure 3). The trans-
lational parameters X-displacement, Y-displacement and Rise
of MB are calculated as defined in Ref. (41) based on the
drug-based axis system (Figure 1). For reasons of clarity, it
should be emphasized that MC trajectories contain ensembles
and do not reflect any timescale of dynamic processes.
The number of 9.4 MC kcycles that was required on average
to establish an MB–DNA complex corresponds to 100 min
CPU time of a Linux-operated 2.7 GHz processor. Thus,
considering the full flexibility of both partner molecules
throughout the docking process, the new MC algorithm
proves to be a highly efficient docking method. Beside the
efficiency, another crucial requirement for successful docking
is the reliability of the binding prediction. Docking into an
intercalation cavity has not been achieved so far by contem-
porary methods and is not likely to occur without the use of
constraints forcing cavity opening throughout the docking
process. Our simulations of MB binding at the surface of a
flexible DNA are performed without the application of any
constraints. In addition, the target-dodecamer is composed
of two hexamers differing in their base sequence. Therefore,
the docking includes the prediction of sequence preferences
of MB–DNA binding.
Of the 20 docking trials 14 (70%) result in minor-groove
binding whereas 5 of the trials (25%) predict major-groove
binding, and only 1 (5%) of them indicates that MB is bound
by stacking interactions to the end base pair of the GC-tract.
The different docking predictions are listed in Table 1 rated
on the basis of the total average energy after binding and
Figure 1. MB and its position throughout the docking process. The drug-based
axis system is depicted in the chemical structure of MB (A). The structural
parameters X-displacement (B) and Y-displacement (C) of MB are shown as a
function of MC cycles during the initial 10 MC kcycles for the docking trial with
the lowest total energy on average. The translational parameters are calculated
based on the position of the drug-based axis system with respect to the DNA
global helix-axis system (41).
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preliminary equilibration was achieved (MC trajectory from
50 to 500 MC kcycles). Remarkably, the 14 of the docking
trials (70%) predicting minor-groove binding are energetically
best rated. In 11 of the minor-groove binding predictions
(78%), MB binds to the AT-tract of the DNA target and in
the remaining 3 (22%) to the GC-tract. A significant drop in
the total energy of 3.5 kcal/mol between docking trials #11
(highest energy for AT-tract binding) and #12 (lowest energy
for GC-tract binding) demonstrates that MB binding in the
minor groove of AT-rich sequences is most favorable. MB is
inserted into the minor groove in two different orientations
with its central sulfur atom either making van der Waals con-
tacts with the floor of the groove or directed outwards the
groove. In the latter orientation, MB’s central nitrogen atom
is inserted into the groove allowing for favorable hydrogen
bonding with the DNA. Interestingly, of the two orientations
of MB within the minor groove the one with the sulfur atom
pointing into the groove is energetically in favor (by 3 kcal/
mol). The two orientations of MB are uniformly distributed
among the docking trials that predict minor-groove binding.
However, the less favored orientation of MB for binding at the
minor groove of the AT-tract (sulfur atom directed outwards)
is the only one shown by minor-groove binding of MB to the
GC-tract.
In four of the AT-tract binding predictions, MB was
bound initially to the GC-tract but migrated throughout the
simulation towards the AT-tract. This migration is illustrated
for the top docking trial (#1 in Table 1) by MC snapshot
conformations (Figure 2) and by the transition from a negative
Rise of MB (i.e. bound to the GC-tract) to a positive Rise
(i.e. bound to the AT-tract) with respect to the reference base
pair 6:C–G in the center of the DNA target (Figure 3). MB
binds to DNA in docking trial #1 within <5 MC kcycles as
illustrated by translational parameters of MB (Figure 1). MB
approaches the DNA backbone in an orientation that does
not enable a stable binding (Figure 2A). Following a re-
orientation of the drug the interaction becomes more favorable
(Figure 2B). This is followed by enhanced contact surface
between the drug and the DNA phosphodiester backbone
that allows for favorable van der Waals interactions as well
as electrostatic attraction between the cationic drug and poly-
anionic DNA phosphate groups (Figure 2C). Starting from
this stabilized binding, MB intrudes the DNA minor groove
first partly with one of its edges (Figure 2D) and then as a
whole (Figure 2E). Thus, major re-orientation of MB induced
by the interplay of attractive and repulsive interactions were
needed to achieve MB binding at the minor groove.
In docking trial #1, MB binds initially at the minor groove
of the GC-tract (Figure 2E) and migrates via the junction
between the two hexamer tracts (Figure 2F) towards the
AT-tract (Figures 2G) finally reaching the center of the AT-
tract (Figure 2H). This migration from the GC- to the AT-tract
minor groove requires 50 MC kcycles reflected by the Rise
of MB (Figure 3), a parameter that describes the drug transla-
tion along the DNA helix axis. The initial MB binding to the
GC-tract (MB Rise of 9.2 s averaged over the first 15 MC
kcycles) changes via distinct transition sites to the AT-tract
(MB Rise of +9.9 s averaged over the last 20 MC kcycles
of the shown period). The MB Rise shows a much smaller
SD of ±0.7 s between 80 and 100 MC kcycles in comparison
with ±5.0 s during the initial 15 MC kcycles indicating the
stabilization of MB binding at the AT-tract minor groove.
The migration of MB from the GC- to the AT-tract demon-
strates an efficient binding-site sampling within a relatively
small number of MC simulation cycles. Notably, in all the
docking trials where MB moved from the GC- to the AT-tract,
the sulfur atom pointed towards the groove’s interior. In con-
trast, the GC-tract binding predictions were characterized by
the opposite orientation of MB. The bulky amino groups of the
guanine bases hinder the migration of MB along the minor
groove. In addition, if MB acts as a hydrogen-bond acceptor
via its central nitrogen atom interacting with guanine amino
groups, this hydrogen bond further hampers transition between
minor-groove binding sites. Such interactions stabilize the
minor-groove binding of MB to the GC-tract in docking trials
#12–14 (Table 1) although migration towards the AT-tract is
probable to occur in longer MC simulations.
Major-groove binding is predicted by only four of the
docking trials (25%). The difference in total average energy
between the least-favorable minor-groove binding and the
most favorable major-groove binding prediction is 3.8 kcal/
mol. The major-groove binding complexes are characterized
by highly variable positions and orientations of the ligand
relative to the target-DNA. MB ‘travels’ and ‘turns’ within
the wide major groove showing intermediate configurations
that are stabilized by non-specific van der Waals contacts
between MB and the DNA. In addition, MB makes excursions
from the center of the major groove towards the polyanionic
phosphodiester backbone where the electrostatic interaction
with the cationic drug contributes to binding.
Table 1. Binding modes and sites achieved by the docking in MC simulations
Trial MC kcycle
until
bindinga
Binding modeb Orientation
of MB in
groovec
Binding
sited
Total
energy on
averagee
1 4.0 Minor groove Sulfur in AT-tract 200.1
2 6.0 Minor groove Sulfur in AT-tract 199.7
3 6.0 Minor groove Sulfur in AT-tract 199.6
4 11.0 Minor groove Sulfur in AT-tract 199.6
5 20.0 Minor groove Sulfur in AT-tract 199.6
6 12.0 Minor groove Sulfur in AT-tract 199.4
7 20.0 Minor groove Sulfur in AT-tract 197.6
8 4.0 Minor groove Sulfur out AT-tract 194.6
9 11.0 Minor groove Sulfur out AT-tract 193.9
10 16.0 Minor groove Sulfur out AT-tract 193.7
11 10.0 Minor groove Sulfur out AT-tract 193.0
12 5.0 Minor groove Sulfur out GC-tract 189.5
13 10.0 Minor groove Sulfur out GC-tract 189.2
14 4.0 Minor groove Sulfur out GC-tract 189.0
15 26.0 Major groove Variable Center 185.2
16 7.0 Major groove Variable GC-tract 185.1
17 3.0 Major groove Variable Center 184.5
18 3.0 Major groove Variable AT-tract 181.1
19 7.0 Major groove Variable GC-tract 179.8
20 3.0 End stacking Variable GC-end 177.8
The number of MC cycles for establishing MB–DNA bindinga is given for
the 20 MC docking trials starting from different positions and orientations of
MB relative to the DNA, complemented by the resulting binding modeb with a
specification of the orientation of MBc (Sulfur in: Sulfur points into the groove;
Sulfur out: Sulfur points outside the groove; Variable: the orientation is vari-
able), and the final DNA-binding site of MBd. The docking trials are ordered
by the average of the total energy (in kcal/mol)e calculated on the basis of every
10th snapshot conformation from 50 to the 500 MC kcycles, hence after
MB binding to DNA was achieved.
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A single docking trial (5%) results in stacking of MB at
the GC-end base pair associated with a rise of 2 kcal/mol in
the average energy compared with major-groove binding.
It should be noted that MB binding by end stacking is due
to the use of a DNA target of a finite length, making this
configuration somewhat artificial but yet an appropriate
model-dependent binding site. Transitions from end stacking
to minor-groove binding in two docking trials (#4 and #8),
both from AT-end stacking, occurred within the initial dock-
ing period as given in Table 1. In case of docking trial #11,
the transition from a long-lasting GC-end stacking to minor-
groove binding occurred only after 143 MC kcycles. The
unfavorable stacking persistence is reflected by the lower
average energy. However, end stacking can be considered as
intercalation-like binding owing to similar stacking inter-
actions. Thus, the higher stability of GC-end over AT-end
stacking refers to the preference of MB to bind GC-rich
sequences by intercalation (40,41).
The strong preference of minor-groove over major-groove
binding (70%) obtained by the docking simulations is in
agreement with available spectroscopic data (40). This result
is remarkable because the insertion of MB into the narrow
minor groove is by far more complex than its insertion into the
spacious major groove. Electrostatic attraction is the major
driving force for the docking of MB onto DNA. Following
this attraction, MB can easily penetrate into the major groove
in any orientation whereas penetration into the minor groove
requires a specific orientation of MB approximately parallel
to the DNA backbone. The prediction of MB binding at the
narrow minor groove is possible because the MC docking
algorithm enables re-orientations of the drug molecule follow-
ing specific interactions at the DNA surface.
The MC docking does not predict intercalation for two
reasons: (i) the formation of an intercalation cavity is
associated with high-energy barriers involving base unstack-
ing, DNA untwisting and transitions to non-canonical back-
bone conformations; (ii) the insertion of the drug into the
cavity and the formation of the intercalation pocket must
occur simultaneously. Spectroscopic data and theoretical
studies have shown that MB minor-groove binding is the
favored binding mode in the case of DNA with alternating
AT base sequence whereas intercalation is favored for DNA
with sequences of alternating GC bases (40,41,43). The
preference of minor-groove binding drugs for AT-rich
sequences is ascribed to favorable hydrophobic and van der
Waals interactions (13,14), which is in accordance with
experimental data for MB and other DNA drugs (4,7,9).
Since an atomic-resolution structure of MB bound to DNA
is not yet available, there is no experimental evidence
regarding the orientation of MB when it is bound at the
minor groove. According to two criteria, prediction statistics
and energy ranking, MC docking of MB to DNA results
in both energetically favorable binding mode and
binding site.
MB–DNA-binding mode transition
We performed MC simulations (2000 MC kcycles) of MB
binding to DNA dodecamers with sequences of alternating
AT or alternating GC bases. The starting configurations of
Figure 2. MC snapshot conformations of MB–DNA docking and binding-site transitions. The docking process is illustrated for the docking trial with the lowest total
energy on average. The upper panel shows MC snapshots after 196 MC cycles (A) 223 MC cycles (B) 262 MC cycles (C) and 280 MC cycles (D). The lower panel
shows MC snapshots after 342 MC cycles (E), 1780 MC cycles (F) 7070 MC cycles (G) and 8740 MC cycles (H). The views are varied by rotations around the DNA
helix axis in order to face the drug-binding site. MB is shown in blue and the two DNA tracts with different alternating base sequences in green (GC-tract) and red (AT-
tract). Note that although the view is rotated there are no major deformations of the DNA target upon minor-groove binding.
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the MC simulations presented here were obtained previously
by energy minimization studies in conjunction with a conti-
nuum treatment of solvent effects (41,43). MB is initially
intercalated in gauche orientation at the central TpA base
pair of the dodecamer with alternating AT sequence (43).
Gauche intercalation describes the rotation of MB by
140 around the DNA helix axis with respect to the parallel
orientation where the long axis of MB is parallel to those of
the flanking base pairs (41). MB is initially intercalated in
parallel orientation at the central CpG base pair of the
dodecamer with alternating GC sequence resulting in dyad
symmetry of the complex as the long axis of MB coincides
with the dyad axis of the DNA (41).
MC snapshot conformations illustrating the transition
from MB intercalation to minor-groove binding are shown
in Figure 4. The intercalation although being energetically
less favorable local-minimum structure (Figure 4A) persists
throughout 1100 MC kcycles, taking 7–8 days CPU time of a
Linux-operated 2.7 GHz processor. During this period, the
structure is getting prepared for the drug release by reversing
non-canonical a/g torsion-angle flips of the DNA backbone.
Several transitions between (gauche, +gauche) and (trans,
trans) conformations of the (a, g) torsion angles at the inter-
calation cavity occur in both directions without binding-
mode implications. The repeated reversal of the a/g-flip in
the first strand towards canonical backbone conformations
after 975 MC kcycles is the essential step that increases the
helix winding at the intercalation site and hence hampers the
stabilizing stacking interactions of the drug with its adjacent
base pairs. Following this, the drug vacates the intercalation
cavity after 1100.2 MC kcycles within only 1 MC kcycle
(Figure 4B and C). The closure of the intercalation cavity
occurs immediately within the following 5 MC kcycles.
However, the binding-mode transition is completed only
after 1125.7 MC kcycles (Figure 4D) when the a/g-flip of
the second strand is replaced by canonical backbone con-
formations. Thus, the binding-mode transition occurs
throughout 25.5 MC kcycles, for which 4–5 h CPU time
are required.
The energetics of the binding-mode transition is shown
in Figure 5 for the trajectory between 1000 and 1200 MC
kcycles. Here, the total energy is decomposed into the three
components: electrostatic, van der Waals and angular defor-
mation energy. The spontaneous drop in the total energy upon
the binding-mode transition is caused by favorable van der
Waals interactions as a result of MB minor-groove binding. In
contrast to the van der Waals energy, there is no significant
variation in the electrostatic energy. The angular deformation
energy becomes more favorable after MB migrates to the
minor groove owing to transitions from non-canonical back-
bone conformations associated with drug intercalation to
canonical ones. In comparison with the spontaneous drop in
the van der Waals energy, the angular deformation energy
decreases in a slower rate along the MC trajectory. However,
a drop in the deformation energy marks the reversal to cano-
nical backbone conformations of the second DNA strand
after 1125.7 MC kcycles.
The energy profiles in Figure 5 clearly identify van der
Waals interactions as the major driving force that induces
the transition from MB intercalation to minor-groove binding.
A detailed trajectory analysis rationalizes the relatively long
trajectory required for this transition as follows. The reversal
of one of the a/g-flips reduces the relative stability of the
intercalation cavity. Also, in a conformational excursion
shortly before the binding-mode transition, a minor-groove
narrowing of the DNA region that eventually absorbs the
drug occurs after 1025 MC kcycles. This groove narrowing
is associated with an inter-strand stacking of adenine bases
that results in a channel-shaped minor groove into which the
drug penetrates after leaving the intercalation site. Figure 5
illustrates that this transition state is characterized by more
favorable van der Waals interactions and higher electrostatic
repulsion owing to shorter inter-strand backbone distances.
Favorable interactions of the drug with the walls of the
DNA minor groove assist in completing the binding-mode
transition.
The conformational MC ensemble has been divided into
two sub-ensembles that represent the initial intercalation
and the final minor-groove binding. Rough conformational
equilibration is usually reached within 250 MC kcycles
from the start of the MC simulation as shown for DNA (17).
After the binding-mode transition, 150 MC kcycles are con-
sidered as rough re-equilibration period. Thus, the MC sub-
ensemble between 250 and 1000 MC kcycles characterizes
intercalation (Phase I), and the MC sub-ensemble between
1250 and 2000 MC kcycles represents minor-groove binding
(Phase II). The average structural and energetic characteristics
Figure 3. Drug position and total energy throughout the docking and migration
of MB. The structural parameter Rise of MB (A) and the total energy of the
system (B), consisting of MB, the DNA target and counter ions, are shown as a
function of MC cycles during the initial 100 MC kcycles for the docking trial
with the lowest total energy on average. The Rise of MB is calculated based on
the position of the drug-based axis system with respect to the plane of the central
6:C–G base pair (41) and illustrates the migration of MB along the minor groove
from the GC-tract (bp 1–6, negative Rise of MB) to the AT-tract (bp 7–12,
positive Rise of MB). The total energy values of every 100th MC snapshot (in
black) are complemented by their smoothed course (in red) and accumulated
averages proving an efficient equilibration (in blue).
Nucleic Acids Research, 2005, Vol. 33, No. 22 7053
of the two sub-ensembles comprised of equal numbers of MC
snapshot structures are given in Table 2.
The average structural parameters of the central base pair
step of the DNA target in Phase I are characteristic of the
intercalation geometry as follows. The large Rise of 7.0 s
is due to the stacking interactions of MB with two adjacent
base pairs at the intercalation site. The low Helix Twist of
26.7 characterizes local helix unwinding and the sugar moi-
eties show O10-endo puckering modes, both were shown to be
associated with intercalation. In contrast to Phase I, the struc-
tural parameters in Phase II (Rise of 3.4 s, Helix Twist of
37.8) are typical of canonical B-DNA since minor-groove
binding does not require major DNA deformations. The
C20-endo sugar puckers are also typical of B-DNA, unlike
the corresponding values at the intercalation site which are
non-symmetrical owing to long-living a/g-flips. SDs of the
structural parameters are given in Table 2, indicating a higher
flexibility of the sugar puckering at the intercalation site in
comparison with sugar moieties in B-DNA environment.
The stabilization of the corresponding binding modes of the
conformational ensembles in Phase I and Phase II is compared
in terms of the various energy components given in Table 2.
Here, we do not analyze the actual transition as shown in
Figure 3 but compare the reasonably equilibrated MC sub-
ensembles of the two different binding modes. Minor-groove
binding is favored over intercalation by 28.9 kcal/mol.
This is contributed mainly by van der Waals interactions
(21.8 kcal/mol) with DNA–DNA interactions (23.6 kcal/
mol) dominating the overall van der Waals effect. In contrast,
van der Waals interactions between MB and the DNA are more
favorable for intercalation than for minor-groove binding by
2.2 kcal/mol owing to stacking interactions. Second among the
energetic contributions stands the angular deformation energy,
which is less favorable for intercalation by 5.7 kcal/mol owing
to non-canonical backbone conformations associated with
backbone elongation at the intercalation cavity.
The difference in electrostatic energy is also in favor of
minor-groove binding over intercalation although to a smaller
extent (1.5 kcal/mol). However, the DNA–DNA electrostatics
favors intercalation by 2.3 kcal/mol since the anionic charges
are more dispersed owing to the helix lengthening. Counter-
ion effects overcompensate the DNA–DNA repulsion through
a more effective ion aggregation at the DNA surface. This
variation in ion–DNA interaction results from ion repulsion
by the cationic drug in the grooves. Thus, MB competes with
the counter ions for DNA-binding sites. Figure 2 shows that
the intercalated MB affects both grooves. However, the drug
molecule does not interfere with ion aggregation in the major
groove in the case of minor-groove binding. Yet, the electro-
static effects are relatively minor, and it should be recalled
that our algorithm uses a simplified implicit solvent descrip-
tion. Despite these approximations, the MC sampling causes
Figure 4. MC snapshot conformations of the MB–DNA-binding-mode transition. The transition from MB intercalation (A) to minor-groove binding (D) is illustrated
in two different orientations: a view into the central minor groove (upper panel) and a view perpendicular to that direction (lower panel). MC snapshots show
the intercalation before the transition after 1100.2 MC kcycles (A), intermediate states after 1100.8 MC kcycles (B) and 1101.3 MC kcycles (C), and the resulting
minor-groove binding after 1125.7 MC kcycles when the backbone has taken up canonical conformations (D). MB is shown in blue and the DNA with alternating
AT base sequence in red.
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a transition from intercalation to minor-groove binding and
yields the energetically favorable binding mode in agreement
with spectroscopic and previous theoretical studies of
MB–DNA binding (40,43).
For reasons of comparison, MC simulations of MB binding
by intercalation to a DNA dodecamer with a sequence of
alternating GC bases were performed with the same protocol.
Here, the binding mode does not alter along the MC trajectory
of 2000 MC kcycles. The data confirm the stability of
MB binding by intercalation to GC-rich sequences (40,41)
although the stacking geometry varies by rotation of the
MB plane around the DNA helix axis as shown in Figure 6.
The symmetric intercalation with MB’s long axis parallel
to the neighboring base pairs represents the predominant
intercalation geometry during the whole MC simulation.
Structural parameters of MB as defined in Ref. (41) character-
ize intercalation modes using the drug-based axis system
shown in Figure 1. In the MC snapshot shown in Figure 6A,
MB is displaced towards the DNA major groove (positive
X-displacement of 0.6 s) and intercalated in parallel
orientation (Helix Twist of 0.0). Frequent conformational
excursions vary the intercalation mode and hence the drug–
DNA stacking geometry. To reach the orientation shown in
Figure 6B, MB ‘turns’ around the DNA helix axis (Helix Twist
of 50.0), which allows for a deeper intrusion of MB into
the intercalation cavity towards the minor groove (negative
X-displacement of1.8 s). Despite the rotational flexibility of
MB within the intercalation pocket, MB returns to the most
stable symmetric intercalation.
Hence, the new MC approach samples the flexibility of the
MB–DNA-binding geometry in dependence on the specific
environment. Transitions between alternative binding sites
and binding modes are assisted by internal MC variables of
the binding partners. In particular, rotatable methyl groups of
the drug and thymine bases act in a ‘gear-wheel’-like manner
with van der Waals ‘cogs’. Interestingly, MB intercalated into
DNA shows a different binding behavior in dependence on
the base sequence. When bound to an AT-rich DNA sequence,
the drug undergoes a transition from intercalation to minor-
groove binding. When bound to a GC-rich DNA sequence,
the drug persists to intercalate throughout the 2000 MC
kcycles. Both results are in accordance with previously
reported experimental data (40) and theoretical binding studies
(41,43). Thus, our new MC algorithm demonstrates the
sequence dependence of MB–DNA-binding modes.
SUMMARY AND CONCLUSIONS
The new MC algorithm for flexible drug–DNA docking has
proven to be both efficient and reliable. The ab initio docking
of MB to DNA can be accomplished fast within 100 min CPU
time. In 70% of the energetically best rated binding predic-
tions, the MC docking results in the energetically favorable
binding mode that is MB minor-groove binding to DNA.
Moreover, the AT-tract as the preferred minor-groove binding
site is predicted by 78% of the corresponding docking trials.
Both the drug and the DNA target are totally flexible and no
constraints are applied during the simulations. The MC simu-
lations sample the interactions of MB with the minor groove
as demonstrated by the migration between different binding
sites.
In addition, our all-atom MC simulations have achieved the
transition between two interaction modes of the drug–DNA
complex, intercalation between base pairs and minor-groove
binding. The change in the binding mode has been analyzed
in terms of structural and energetic aspects showing that van
Figure 5. Energy variation upon the MB–DNA-binding-mode transition. The energy components and total energy are shown as a function of MC cycles for the part of
the trajectory between 1000 and 1200 MC kcycles that includes the transition from MB intercalation to minor-groove binding. The binding-mode transition occurs
shortly after 1100 MC kcycles. MC snapshot values of every 100th MC cycle (in black) are complemented by their smoothed course over the MC trajectory (in red).
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der Waals interactions are the driving force for this conver-
sion. DNA deformations upon intercalation, such as cavity
opening, helix unwinding and non-canonical conformations
of the sugar-phosphate backbone, converge to structural para-
meters of B-DNA, which are characteristic of minor-groove
binding. The migration between alternative binding sites
and the transition between binding modes in reasonable simu-
lation periods is achieved owing to the flexibility of the
binding partners. Moreover, the transition between binding
modes depends on the DNA base sequence. In accordance
with experimental data, MB intercalation changes into
minor-groove binding for AT-rich DNA but is stable for
GC-rich DNA. Hence, the effect of the base sequence on
drug–DNA-binding modes becomes a realistic object of
molecular modeling in drug design studies in particular,
and for understanding molecular recognition in biological
processes in general.
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